Gracell Biotechnologies Inc.

$

USD

	Dec '18	Dec '19	Dec '20	Dec '21
revenue				366K -
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	10.26M -	27.36M 1.67%	45.57M 66.53%	137.04M 2.01%
selling general and administrative expenses	10.26M -	27.36M 1.67%	45.57M 66.53%	137.04M 2.01%
research and development expenses	52.24M -	119.22M 1.28%	168.83M 41.61%	326.90M 93.63%
other expenses
cost and expenses	62.50M -	146.58M 1.35%	214.40M 46.27%	463.94M 1.16%
operating expenses	62.50M -	146.58M 1.35%	214.40M 46.27%	463.94M 1.16%
interest expense			2.15M -	5.06M 1.35%
ebitda	-57.80M -	-133.54M 1.31%	-188.16M 40.90%	-386.42M 1.05%
operating income	-62.50M -	-146.58M 1.35%	-214.40M 46.27%	-463.57M 1.16%
depreciation and amortization	2.99M -	5.12M 71.26%	21.59M 3.21%	60.27M 1.79%
total other income expenses net	1.71M -	7.92M 3.63%	2.50M 68.47%	11.82M 3.74%
income before tax	-60.79M -	-138.66M 1.28%	-211.90M 52.82%	-451.75M 1.13%
income tax expense
net income	-60.79M -	-138.66M 1.28%	-211.90M 52.82%	-451.75M 1.13%
weighted average shs out	19.81M -	36.97M 86.62%	19.81M 46.41%	104.90M 4.30%
weighted average shs out dil	19.81M -	36.97M 86.62%	19.81M 46.41%	107.49M 4.43%
eps	-3.68 -	-3.75 1.77%	-13.85 2.69%	-4.31 68.91%
epsdiluted	-3.68 -	-3.75 1.77%	-13.85 2.69%	-4.20 69.65%

All numbers in USD (except ratios and percentages)